Nasdaq · CIK 0001743881 · PHARMACEUTICAL PREPARATIONS
BridgeBio Pharma, Inc.
BBIO chart by TradingView
PRICE HISTORY
LIVE · NASDAQBBIO chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.5B
- EBITDA
- $-0.5B
- FREE CASH FLOW
- $-0.4B
- EPS
- $-3.83
- GROSS MARGIN
- 95.82%
- ROIC
- 112.87%
Q1 FY26ENDED MAR 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 23 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
—
⤢
P / SALES (TTM)
24.9x
-75%14.5x708.7x
⤢
P / BOOK
—
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
28.0x
-71%15.2x716.3x
⤢
FCF YIELD (TTM)
-3.08%
+1.7pp-37.64%-3.05%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.2B
+627%⤢
EBITDA (DERIVED)
$-0.1B
+$0.0B⤢
NET INCOME
$-0.2B
$0.1B⤢
EPS (DILUTED)
$-0.86
$0.16⤢
REVENUE GROWTH YOY
66.78%
-199.9pp-97.77%11461.88%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
-101.46%
+86.9pp-40213.61%3443.22%
⤢
RETURN ON CAPITAL
144.42%
+81.7pp31.74%144.42%
⤢
RETURN ON EQUITY (TTM)
—
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN94.89%
OPERATING MARGIN-54.47%
NET MARGIN-85.63%
FCF MARGIN-101.46%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$-0.2B
$0.1B⤢
STOCK-BASED COMP
$0.0B
+475%⤢
CAPITAL EXPENDITURE
$0.0B
-82%⤢
SHARES OUTSTANDING
0.19B
+33%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.9B
+113%⤢
TOTAL DEBT
$2.7B
+3436%⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 99.07%INSIDERS 3.92%OTHER / RETAIL 0.00%639 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 7.27% | 14.2M | $1.20B | -2.4% |
| Kohlberg Kravis Roberts & Co. L.P. | 6.78% | 13.3M | $1.12B | +0.0% |
| Janus Henderson Group PLC | 6.74% | 13.2M | $1.11B | +19.8% |
| Viking Global Investors, L.P. | 6.06% | 11.8M | $1.00B | -17.7% |
| Farallon Capital Management LLC | 4.79% | 9.4M | $791.2M | NEW |
| Vanguard Portfolio Management LLC | 4.13% | 8.1M | $682.6M | NEW |
| Vanguard Capital Management LLC | 3.97% | 7.8M | $655.5M | NEW |
| Aisling Capital Management LP | 2.60% | 5.1M | $430.0M | +0.0% |
| State Street Corporation | 2.52% | 4.9M | $416.9M | -0.6% |
| Geode Capital Management, LLC | 2.52% | 4.9M | $415.5M | +11.5% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.